Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 13-16, 2025.

Company Presentation Details:

Date: Monday, January 13, 2025
Time: 9:45-10:25 AM Pacific Time (12:45-1:25 PM Eastern Time)
Webcast: Register here

Presenter: Ian Mortimer, President and Chief Executive Officer, Xenon Pharmaceuticals

A live audio webcast of the company presentation will be available on the “Investors” section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com

For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com

Staff

Recent Posts

CONMED Corporation to Announce Second Quarter 2025 Financial Results on July 30, 2025

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for…

12 hours ago

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025

MARLBOROUGH, Mass.--(BUSINESS WIRE)--$HOLX #earnings--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release…

12 hours ago

inTouch Addresses $6.7 Billion Senior Loneliness Crisis with Launch of AI Conversational Companion for North America

Complements Family Interactions & Supports Sandwich Generation of Caregivers with Daily Phone Calls to Seniors…

12 hours ago

AI in Healthcare: MENA Region on the Verge of a Major Breakthrough

"Comprehensive Analysis of MENA's AI Healthcare Market: Emerging Opportunities and Challenges, with a Projected CAGR…

12 hours ago

Global Excel Acquires First Assistance to Strengthen Assistance Services and Expand in the Asia-Pacific Market

SHERBROOKE QC, July 2, 2025 /PRNewswire/ - Global Excel Management Inc. (Global Excel) is pleased…

12 hours ago

Single Pass Inc. Launches Global Post-Market Evaluation of the Biopsy Tract Closure Device

The evaluation will include 1,000 unique procedures across 20 centers worldwide to capture real-world evidence…

18 hours ago